All In Biotech

Drug Trial Radar · NCT07847697

A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, PK/PD Characteristics, and Efficacy of SCTB10

A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Single and Multiple Doses of SCTB10 in Healthy Participants and Patients With Hemophilia A

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Jun 30, 2029

Study completion Aug 30, 2029

Sponsor

Lead sponsor
Sinocelltech Ltd.Industry
Sponsor type
Industry
First posted
Sep 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Phase Ia to evaluate the safety, tolerability, immunogenicity, and pharmacokinetics of SCTB10 following a single dose in healthy participants

Conditions

  • Healthy Participants

Interventions

  • SCTB10Drug

    SCTB10 will be subcutaneously administered as a single dose in healthy volunteers

  • PlaceboDrug

    Placebo will be subcutaneously administered in Healthy Volunteers

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. dose limited toxicity (DLT).Time frame: Up to approximately 6 weeks.
  2. Incidence of TEAE.Time frame: Up to approximately 25 weeks.
  3. Incidence of TRAE.Time frame: Up to approximately 25 weeks.
  4. Incidence of SAE.Time frame: Up to approximately 25 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.